

Resource Summary Report

Generated by [RRID](#) on Sep 2, 2026

PC-9

RRID:CVCL_B260

Type: Cell Line

Proper Citation

RRID:CVCL_B260

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_B260

Proper Citation: RRID:CVCL_B260

Description: Cell line PC-9 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung adenocarcinoma

Defining Citation: [PMID:758928](#), [PMID:1737336](#), [PMID:1847845](#), [PMID:4094096](#), [PMID:8263009](#), [PMID:9023415](#), [PMID:9178645](#), [PMID:9538136](#), [PMID:10536175](#), [PMID:11005564](#), [PMID:11078804](#), [PMID:16105816](#), [PMID:17332333](#), [PMID:17511773](#), [PMID:19472407](#), [PMID:19799608](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:22313637](#), [PMID:23733853](#), [PMID:25877200](#), [PMID:26202522](#), [PMID:26554430](#), [PMID:28196595](#), [PMID:28290473](#), [PMID:29681454](#), [PMID:31068700](#), [PMID:34320349](#), [PMID:38639832](#), [PMID:39061985](#)

Comments: Population: Chinese; Han and Japanese., From: Immuno-Biological Laboratories (IBL); Tokyo; Japan., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: PC-9

Synonyms: PC9, PC-9/S1, PC-9S1

Cross References: BTO:BTO_0005518, CLO:CLO_0050067, EFO:EFO_0002847, BCRJ:0331, BioGRID_ORCS_Cell_line:1203, BioSample:SAMN03470946,

BioSample:SAMN10989619, cancercellines:CVCL_B260,
Cell_Model_Passport:SIDM00236, ChEMBL-Cells:ChEMBL3307867, ChEMBL-
Targets:ChEMBL614102, CLS:305045, Cosmic:713867, Cosmic:801574,
Cosmic:876137, Cosmic:897746, Cosmic:911753, Cosmic:915329, Cosmic:917985,
Cosmic:929156, Cosmic:946058, Cosmic:1001658, Cosmic:1002731, Cosmic:1047092,
Cosmic:1128254, Cosmic:1146943, Cosmic:1239896, Cosmic:1336875, Cosmic:1571735,
Cosmic:1656893, Cosmic:1731370, Cosmic:1745414, Cosmic:2015224, Cosmic:2125285,
Cosmic:2668307, DepMap:ACH-000779, ENCODE:ENCBS177ANS,
ENCODE:ENCBS480XRH, ENCODE:ENCBS761VSF, ENCODE:ENCBS987JQH,
GEO:GSM434290, GEO:GSM481160, GEO:GSM784274, GEO:GSM794406,
GEO:GSM827407, GEO:GSM1374821, GEO:GSM5599283, IARC_TP53:2385,
IGRhCellID:PC9GEO, LINCS_HMS:50038, LINCS_LDP:LCL-1630, PRIDE:PXD001548,
PRIDE:PXD002224, Progenetix:CVCL_B260, PubChem_Cell_line:CVCL_B260,
RCB:RCB4455, Ubigen:YC-C114, Wikidata:Q54938469

ID: CVCL_B260

Record Creation Time: 20220427T221414+0000

Record Last Update: 20260829T235553+0000

Ratings and Alerts

No rating or validation information has been found for PC-9.

No alerts have been found for PC-9.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 689 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Chen Y, et al. (2026) Cholesterol Promotes Lung Adenocarcinoma Brain Metastasis by Stabilizing EGFR Protein to Drive EMT, Metabolic Reprogramming, and Premetastatic Niche Formation. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(17), e73843.

Zhang Y, et al. (2026) Single-cell and spatial transcriptome analyses reveal tumor immunometabolism in lymph node metastasis of lung cancer. *Cancer biology & medicine*.

Pan K, et al. (2026) Lysine methylation-mediated SMYD2 degradation by casticin sensitizes non-small-cell lung cancer cells to osimertinib therapy. *Biochemical pharmacology*, 243(Pt 2), 117562.

Zhang Y, et al. (2026) Targeting IRF1-TRIM21 axis enhances anti-tumor immunity by promoting ubiquitin-mediated degradation of FGL1 in non-small cell lung cancer. *Communications biology*, 9(1).

Wang F, et al. (2026) Extracellular vesicles derived from cancer-associated fibroblasts facilitate NSCLC progression and metastasis via miR-664b-5p-mediated activation of the CXCL12/CXCR4 chemokine pathway. *Biochimica et biophysica acta. Molecular basis of disease*, 1872(8), 168360.

Kim NY, et al. (2026) Multimodal cell death induced by indirubin-3'-oxime through inhibition of Akt/mTOR axis in lung cancer cells. *Chemico-biological interactions*, 423, 111851.

Ma C, et al. (2026) Effect of isoginkgetin on targeting methylenetetrahydrofolate dehydrogenase 2 to induce ROS-mediated apoptosis in non-small cell lung cancer. *Phytomedicine : international journal of phytotherapy and phytopharmacology*, 159, 158425.

Lee EJ, et al. (2026) JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(9), 1835.

Liu Y, et al. (2026) Mitofusin-2 suppresses tumor immune escape through EGFR/STAT3-mediated PD-L1 transcription. *Cell death & disease*, 17(1).

Cheng Y, et al. (2026) JAK inhibitors alleviate EGFR-inhibitor-induced diarrhea by protecting intestinal stem cells from adaptive-immune-exacerbated injury. *Nature communications*, 17(1).

Wang X, et al. (2026) Oxidative stress-driven m5C methylation by NSUN5 confers cisplatin resistance in lung adenocarcinoma through promoting glycolysis. *Redox biology*, 94, 104193.

Liao J, et al. (2026) Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer. *Cancer cell*, 44(7), 1401.

Wang Y, et al. (2026) A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC. *Cellular oncology (Dordrecht, Netherlands)*, 49(1), 31.

Wen T, et al. (2026) SATB2 Mediates H3K9 Delactylation by Recruiting HDAC3 to Repress LCN2 and Inhibit Lung Tumor Growth and Metastasis. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(19), e22996.

Li H, et al. (2026) PDZRN4 suppresses lung adenocarcinoma progression via inhibiting ubiquitin-mediated HIF-1A degradation. *Oncogene*, 45(4), 577.

Wang F, et al. (2026) Lactate Facilitates the Survival and Invasion of Pancreatic Cancer Cells Under Glucose Deprivation. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 40(7), e71726.

Vendramin R, et al. (2026) Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome. *Immunity*, 59(5), 1398.

Wu K, et al. (2026) Cuproptosis and Mitophagy Mediated by the THUMP1/IGF2R-Dependent Suppression of AKT and Activation of AMPK Signaling Suppress Lung Adenocarcinoma Progression. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(42), e21238.

Rurka P, et al. (2026) A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose-driven glioblastoma. *Molecular oncology*.

Ge Y, et al. (2026) MTF1 promotes VDAC1 oligomerization to reprogram BCAA metabolism in tumor cells to polarize TAMs in LUAD. *Cell death & disease*.